Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
With over half of US adults meeting eligibility criteria across the three major indications, understanding the distribution of eligible individuals and their insurance status is crucial
A systematic research review
22.5% PBO-adjusted weight loss at 48 weeks, comparable to retatrutide and ahead of tirzepatide's SURMOUNT-1
Click on the links below to view the notifications published by the Department of Health & Social Care, plus the guidance document from ABCD & PCDS: Medicine Supply Notification (MSN/2023/061) National Patient Safety Alert: Shortage of GLP-1 receptor agonists Guidance from ABCD & PCDS: GLP-1 RA National Shortage Tell a colleague Share this programme with your colleagues
US$ 25.55
US$ 29.24
US$ 20.72
US$ 24.01
US$ 28.08
US$ 28.32
